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Manipulation of gene expression in developing or in mature central nervous
systems (CNS) holds a promise for the resolution of many compelling neurobio-
logical questions, including the feasibility of gene therapy to treat diseases of
the brain. In this context, a number of viral vectors have been used in recent
years to introduce and express genes into the CNS. This article discusses a gene
transfer system based on the Herpes Simplex Virus-1 (HSV-1). We describe here
the use of non-replicating, non-toxic HSV-1 vector, 8117/43, in a series of stud-
ies carried in our joint program. This vector proves further the utility of HSV-1 as
a delivery vehicle to a number of distinct sites within the CNS.
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INTRODUCTION
Interest in introducing genes into the CNS has fo-
cused attention on a number of viral vectors. Sever-
al aspects of the natural biology of HSV-1 make it an
attractive vector for delivering and expressing for-
eign genes within the nervous system. First and fore-
most is the fact that HSV-1 is a neurotropic virus
possessing a sophisticated genetic program allow-
ing it to spend most of its life cycle within the ner-
vous system. HSV-1 enters neurons at the periphery
and travels via axonal transport to the cell bodies of
the sensory ganglia where it becomes latent [18,20].
HSV-1 has the capacity to travel transynaptically far
from its original site of infection. In humans, most
infections are sub-clinical, and by age 20 approxi-
mately 90% of the population has been exposed to
HSV-1. During latency the viruss 152 kb double-
stranded DNA genome persists as circular episomes
within the nuclei of neurons. It is the ability of the
virus to naturally co-exist within the nervous system
without causing disease (or provoking the immune
system) that suggests its suitability as a vector. Some
of the key advantages of HSV-1 vectors are that: 1)
they establish a life-long latent infection within pe-
ripheral and CNS neurons; 2) latent HSV-1 genomes
exist as multiple episomal copies per neuron and in-
tegration is not known to occur [16]; and 3) non-
replicating HSV-1 recombinants can establish a la-
tent infection efficiently [17]. This last point is per-
haps the most important in that it permits the
construction of safe, attenuated vectors for human
gene therapy. In addition, there are other biological
properties of HSV-1 which enhance its suitability as
a vector from a practical standpoint. The virus is easy
to manipulate in vitro, so that recombinants con-
taining foreign genes can be constructed rapidly and
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its genome can accept large inserts of DNA, making
the construction of vectors (which express multiple
therapeutic genes) feasible. This potential has un-
derstandably generated a great deal of interest in
exploiting HSV-1 as a vector [10], and to date a num-
ber of recombinants have been generated express-
ing reporters such as b-galactosidase [1,5,6,9], as well
as biologically relevant peptides such as glucou-
ronidase [21], tyrosine hydroxylase [7] and nerve
growth factor (NGF) [8,14]. These vectors include
both recombinant HSV-1 and a derivative termed
amplicons. Here we will be discussing only the
former.
Engineering of HSV-1
Early viral constructs expressed their respective mark-
ers transiently at high levels, however, the expres-
sion declined rapidly with time. While for some ther-
apeutic applications transient expression of a pep-
tide within target neurons may be sufficient, for most
uses long-term expression from the latent infection
is desirable. Stable expression of genes from the
context of the latent viral genome has proven the
most difficult problem to solve in the development
of HSV-1 vectors. Since latent infections of HSV-1
are characterized by the absence of viral transcrip-
tion (with the exception of the latency associated
transcript, LAT [19]), the LAT promoter would be the
ideal candidate for the expression of foreign genes
during latency. However, recombinant viruses con-
taining the genes for nerve growth factor and b-ga-
lactosidase driven by the LAT promoter express b-
galactosidase and NGF RNA at high levels initially,
but not during the latent infection [14]. A weaker
promoter downstream of the LAT promoter (LAP2)
has also been shown to be insufficient for long-term
expression. A number of cellular promoters, includ-
ing those for neuronal housekeeping genes, have
been evaluated for their long-term ability to express
genes in the nervous system within the context of
the HSV-1 genome. These constructs expressed re-
porter genes at high levels during the acute infec-
tion (for a period of 210 days p.i.) but the levels of
expression dropped off dramatically following the
latent infection [3]. The Moloney Murine Leukemia
Virus (MoMuLV) LTR has been demonstrated, how-
ever, to afford long-term expression of b-galactosi-
dase [4,6] in the context of the LAT promoter [13].
This combination of the LAT-core promoter and the
MoMuLV LTR allows extended expression of trans-
genes at high levels within the sensory neurons of
the peripheral nervous system [14], but only mini-
mal levels of sustained expression within the CNS
[4]. Recently, the native region of the HSV-1 genome,
which may allow sustained expression, has been fur-
ther localized to an element downstream of LAT,
termed LTE for long-term expression [2,12]. In addi-
tion, there is also evidence that a region upstream
of the LAT core promoter may play a role in enhanc-
ing long-term expression properties [15]. Clearly the
regulation of this region is complex, but enough
details are now available that reasonable levels of
long-term expression in the CNS can be achieved
for at least several weeks, which is sufficient for a
variety of research applications.
In the following section we describe the use of
the non-replicating HSV-1 vector, 8117/43. This vec-
tor is ICP4 minus [i.e., it has the major viral transac-
tivator gene (Infected Cell Protein 4; ICP4) deleted]
and is completely non-replicating and must be prop-
agated on a helper cell line that provides the ICP4
gene in trans. As shown in Figure 1, this vector con-
Figure 1. Diagram of the non-replicating HSV-1 recombinant 8117/43. The HSV-1 genome (top) is double stranded DNA 150 kb in length
and is comprised of 4 components: the unique long (UL) and unique short (US) segments (indicated by the thin lines), and the long repeat
(RL) and short repeats (indicated by the stippled boxes, and black boxes, respectively). The region comprising the junction of one of the
long repeats and one of the short repeats is expanded below the diagram to illustrate the site into which the E.coli LacZ has been inserted
in place of the ICP4 gene of the virus, driven by the LAT/MoMuLV LTR promoter (see text). KD6, and ICP4-minus virus made by transfect-
ing HSV-1 strain KOS DNA with engineered plasmid DNA in which most of the coding sequence for ICP4 had been deleted, served as a
control virus in some of our experiments.
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tains the E. coli LacZ gene driven by the LAT/Mo-
MuLv LTR promoter [6]. This vector demonstrates the
utility of HSV-1 as a delivery vehicle to a number of
distinct sites within the CNS.
METHODS
Animal groups
Adult Male Fischer 344 rats (n = 27) Harlan Spra-
gue-Dawley Inc., NIA colony) with average body
weight 250 g were used. The animals were housed
in the Laboratory Animal Facilities in the School of
Medicine and Biomedical Sciences at the State Uni-
versity of New York at Buffalo. They were kept in
stainless steel wire cages in a room with 12 hours
light/dark cycle, and were fed a standard laboratory
diet (Prolab R-M-H 1000, Agway Inc., Syracuse, NY)
and water ad libitum. Before surgery, animals were
randomly assigned to one of three groups:
I. Experimental group, inoculated with HSV-1 (8117/
43) [4 ml, 3 x 106 plaque forming units (PFU) per
injection site] (n = 14).
II. Control group, injected with 4 ml of 5% glucose
per injection site (n = 9).
III.Control group inoculated with HSV-1 (KD6) lack-
ing b-galactosidase reporter gene (4 ml, 3 x 106
PFU per injection site) (n = 4).
All rats were inspected visually each day and
weighed each week to monitor health. All procedures
were approved by the Institutional Animal Care and
Use Committee guidelines (IACUC) of the State Uni-
versity of New York at Buffalo.
Stereotaxic inoculation
Each animal was weighed then deeply anesthetized
with a mixture of ketamine (100 mg/ml), xylazine
(20 mg/ml), and ace-promazine (10 mg/ml) in 0.9%
NaCl (0.2 ml/100 g body weight, i.p.). The rat was
situated in the stereotaxic apparatus, and the skull
was revealed through a 1cm incision. Bregma loca-
tion was recorded and the surgical coordinates were
established for the injection sites. A 1 mm hole for
each injection site was drilled in the skull using a
dental drill. Stereotaxic intracerebral injections were
performed using 30 G stainless steel needle of the
10 ml Hamilton syringe held by the micromanipula-
tor on the stereotaxic apparatus. Rats in all groups
were injected with 4 ml/injection site of the proper
solutions. The solutions were injected at 1 ml/min,
and the injection was followed by a 4 min waiting
period before the needle was removed from the
brain.
Injection sites
Each rat was stereotaxically injected bilaterally in the
rostral hippocampus and substantia nigra. The fol-
lowing coordinates were used to inject into the hip-
pocampus: Anterior-posterior (AP): 3.60 mm, me-
dial-lateral (ML): –2.40 mm and dorsal-ventral (DV):
3.40 mm. Substantia nigra coordinates were: AP: 
5.60 mm, ML: –1.50 mm., and DV: 8.20 mm. After
the last injection, the incision was closed with bio-
degradable sutures and the rats were housed one
per cage, and their health was closely monitored until
full recovery.
Survival duration following surgery
All groups were divided into three subgroups accord-
ing to the time of sacrifice post injection:
Short term (ST): sacrificed at 5 days post-injection
Mid term (MT): sacrificed at 14 days post-injection
Long term (LT): sacrificed at 26 days post-injection
Tissue preparation and histochemical
procedures for the detection of b-galactosidase
At various times post injection, each rat was deeply
anesthetized (0.8 cc, i.p.) as determined by the ab-
sence of responses to afferent stimuli. Rats were
perfused transcardially by 100 mM PBS (pH 7.3) so-
lution followed immediately by ice-cold fresh 4%
paraformaldehyde fixative in 0.1 M phosphate-buff-
er (pH 7.3). Rats were decapitated, brains were re-
moved and placed in the 4% paraformaldehyde fix-
ative solution. Brains were cut into 1 mm coronal
sections using stainless steel brain mold. During cut-
ting, brain tissue was moistened by paraformalde-
hyde to prevent drying. These 1mm serial sections
were transferred into individual wells of 12-well dish
and post fixed with 2% formaldehyde, 0.2% glut-
araldehyde, 0.1% sodium deoxycholate and 0.02%
NP-40 in 100 ml of 100 mM PBS for 1 hour at 4oC.
Following post fixation, tissue was washed twice
with PBS followed by one wash with 3% DMSO/
PBS. The X-gal staining solution consisted of 0.87g
NaCl, 100 mM HEPES (pH 7.5) 2 mM MgCl2, 0.01%
sodium deoxycholate, 0.02% NP-40, 5 mM potassi-
um ferricyanide, 5 mM potassium ferrocyanide. This
solution was freshly prepared and kept at 4oC. When
ready to use, the solution was warmed to 36oC and
5 ml of 2 % X-gal [5-bromo-4-chloro-3-indolyl b-D-
galactopyranoside] in dimethyl formamide were
added. Tissues were stained with X-gal for 7 hours
at 31oC in the dark. Subsequently, the slices were
washed several times in PBS and placed in 30% su-
crose in PBS. All solutions were prepared fresh and
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their pH was adjusted above 7.2 in order to pre-
vent the detection of endogenous (acidic) b-galac-
tosidase. Digital pictures were taken and the tis-
sues were further cut into 50 mm sections using a
freezing microtome. Brain sections were mounted
onto gelatin subbed slides, counter stained with
Eosin Y, then subjected to routine dehydration
through ethanol. Finally, sections were passed
through xylene and cover slipped with paramount.
DNA and RNA extraction from dissected
samples of rat CNS
Homogenization of tissue: Frozen tissue samples
were homogenized in a total of 4 ml of Trizol (Life
Technologies, Gaithersburg, MD). The solution was
collected in a microcentrifuge tube and incubated
for 5 min at room temperature. Following incuba-
tion, 200 ml of chloroform was added to each sam-
ple and samples were vortexed for 15 sec. Samples
were then incubated for an additional 5 min at room
temperature, and microfuged at 9,000 x g (10,500 rpm
in a Brinkman microfuge) for 15 min at 4°C to ensure
separation of the aqueous and organic phases.
Extraction of the RNA fraction: The aqueous phase
was removed and transferred to a clean microcentri-
fuge tube and 500 ml of isopropanol was added. The
tube was shaken for 15 sec, incubated for 5 min at
room temperature and then microfuged at 9,000 x g
for 10 min. The samples were washed with 75% etha-
nol (made with DEPC-treated water) and centrifuged
for 5 min at 4°C at 8,500 rpm. The RNA pellet was air
dried, resuspended in 200 ml of DEPC-treated water,
and incubated for 510 min at 55°C to resuspend the
RNA. 100 ml of the 200 ml sample was DNase-treated
with RNase-free DNase (Stratagene), using 2040 U in
20 mM Tris, pH 7.4; 10 mM MgCl2 for 30 min at 37°C.
DEPC water was added to bring the total volume to
200 ml, the sample extracted with phenol/chloroform/
isoamyl (mix phenol 1:1 to chloroform/isoamyl) (chlo-
roform/ isoamyl 24:1) extract in (1:1) ratio. The aque-
ous layer was taken and extracted again with chloro-
form/isoamyl (1:1). The aqueous layer was taken and
transferred to a new centrifuge tube and the RNA pre-
cipitated by adding 1/50 volume of 5 M NaCl and 2.5
volume of 100% ethanol. The samples were mi-
crofuged at 14,000 rpm in the Brinkman microcentri-
fuge for 15 min at 4°C. The tubes were rinsed with
1 ml of 75% ethanol and microfuged for an additional
5 min at room temperature and briefly air-dried. The
RNA was resuspended in 50 ml DEPC-treated water.
Preparation of cDNA: 0.5 mg of RNA (usually in 5
10 ml of the sample from above) was reverse-tran-
scribed into cDNA. The reaction volume of 20 ml con-
tained: 510 ml of sample RNA, 4 ml of 5x RT buffer
(Life Technologies), 1 ml (10 pmol) random hexamer
primers (Pharmacia), 1 ml 12.5 mM cold dNTPs (Phar-
macia), 1 ml MoMuLV RT (Life Technologies), 0.5 ml
RNasin (Promega). The samples were mixed gently for
12 sec and then incubated at 37°C for 1 hour. The
reactions were stopped by heating at 100°C for 10 min,
then quenched on ice and microfuged for 12 sec.
PCR reactions: The PCR reactions were set up as
follows: 5 ml of 10X PCR buffer (1.5 mM Mg), 1 ml of
dNTP (12.5 mMol), 1 ml of primer 1, 1 ml primer 2,1 ml
of the cDNA sample, 0.5 ml of Taq (Perkin-Elmer),
40.5 ml of water for a 50 ml total reaction. The PCR
conditions for detection of the b-gal transcripts were
94°C, 55°C, 72°C for 3 min (1X) and 94°C, 55°C, 72°C
for 1 min (30X). The primer set for b-gal detection: Primer
1: 5ATG GCT GAC TGG GGG GCA TAT3’; Primer 2:
5GCA CAG TGA AAT CGT TAA TAT3’.
RESULTS
Gene therapy, a procedure which employs the use
of viral vectors to deliver therapeutic genes into neu-
ronal cells, has exciting clinical implications as a tool
for treating human neurodegenerative diseases. In
this context, two candidate neural systems, the bas-
al forebrain-hippocampal projection implicated in
Alzheimers and the nigrostriatal pathway implicat-
ed in Parkinsons, appear to be model systems to
test gene therapy procedures. Using these two neu-
ral pathways, we investigated the expression of b-ga-
lactosidase reporter gene following the injection of
non-replicating HSV-1.
Injection into hippocampus
Inoculation of the 8117/43 virus into the rostral hip-
pocampus resulted in strong expression of recombi-
nant viral b-galactosidase activity with a great num-
ber of cells labeled around injection site (Fig. 2A). At
5 days post injection the stained region extended at
least 3 mm in the anterolateral direction and 35 mm
in mediolateral direction (Fig. 2A,B). Scattered cells
of the medial septum/diagonal band were positively
stained following injection into this region (Fig. 2B).
This may be a result of retrograde transport of the
virus. Figure 2C shows labeling of hippocampal neu-
rons.
The initial (i.e., 5 days) strong expression in the
hippocampus was significantly reduced 15 days post-
inoculation and little or no expression was detected
26 days post-inoculation. (Fig. 2A). The expression
of b-galactosidase activity in basal forebrain was tran-
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Figure 2. Histochemical detection of recombinant b-galactosiadse activity in the hippocampal, striatal, and basal forebrain regions. Rats
received a bilateral inoculation of HSV-1 8117/43 or injection of 5% glucose (control) into rostral hippocampus and substantia nigra.
A) 1 mm sections photographed immediately following incubation with X-gal staining solution for 7 hours. X-gal staining (dark blue) de-
tects the expression of exogenous b-galactosidase following the injection of 4 ml of b-galactosidase DNA. HSV-1 (8117/43) injection pro-
duces widespread expression of the reporter gene b-galactosidase in the hippocampus at 5 days post injection. The expression was de-
creased significantly at 14 days post injection until it disappeared at 26 days. No exogenous b-galactosidase activities were detected in
the hippocampal regions in the control sections. Minor blue background was evident in some 1 mm sections especially at the needle
tracks and choroids plexus regions, however, this blue background was not cellular (see figures 2C and 3C).
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Fig. 2B. Three consecutive 1 mm coronal sections throughout the rat hippocampus. HSV-1 8117/43 vector or 5% glucose (control) was
injected bilaterally into the hippocampal region. The activities of recombinant b-galactosidase were revealed five days post injection by
the chemical reaction with X-gal (dark blue). Sections show b-galactosidase expression in the hippocampus following the use of HSV-1
8117/43 as a vector. No b-galactosidase expression in the control sections was detected. H  hippocampus, S  substantia nigra, DB
 nucleus of the diagonal band.
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Fig. 2C. Expression of b-galactosidase in the hippocampus inoculated with HSV-1 8117/43 (10x). The neurons expressed b-galactosidase
activity in soma and dendrites (Figure at the right, 20x). Five days post injection (50 mm sections).
sient (similar to hippocampal expression). In control
brains injected with 5% glucose solution no staining
was detected at any time after injection.
Injection into substantia nigra
Initially (i.e., 5 days), inoculation into the substantia
nigra resulted in a relatively weak X-gal staining, re-
flecting limited number of neurons expressing b-ga-
lactosidase activity (Fig. 3A). An X-gal positive neu-
ron in the zona compacta of the substantia nigra is
shown on Figure 3B. Interestingly, with time the ex-
pression of b-galactosidase activity increased, and
26 days after the inoculation a great number of cells
showed strong b-galactosidase activity (Fig. 3A,C).
No staining was observed at any time in control
brains injected with glucose (Fig. 3A,C). Also, in
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Figure 3. Figure represents the results of the stereotaxic injection of HSV-1 8117/43, control HSV-1 KD6, or 5% glucose into the substan-
tia nigra region.
A) Expression of b-galactosidase in substantia nigra at several time points post injection (1 mm brain sections) (10x).
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Fig. 3B. Expression of b-galactosidase by HSV-1 8117/43  in substantia nigra neurons (40x). Five days post injection (50 mm sections).
brains inoculated with control HSV-1 (KD6) no b-ga-
lactosidase activity was detected (Fig. 3D).
Spread of the virus from the substantia nigra was
examined by determining whether specific staining
was present in the striatum after virus injection. A
transient X-gal staining in the striatum was observed
at 5 days and only trace amounts at 14 days follow-
ing the virus injection (Fig. 2A,B). Under higher mag-
nification the staining was localized to striatal neu-
rons, apparently due to retrograde transport of the
virus by the striatonigral pathway (data not shown).
To ascertain that the HSV-1 8117/43 remained in
the substantia nigra region for an extended period
of time, the presence of viral DNA was examined
using PCR 26 days after the inoculation. Viral DNA
remained present for almost 1 month after the inoc-
ulation (Fig. 4).
Unlike earlier studies which utilized HSV-1 ampl-
icon that may be contaminated with helper virus
[7], no pathological changes (i.e. gliosis, neuronal
degeneration) were detected in brain regions inocu-
lated with HSV-1 8117/43.
DISCUSSION AND CONCLUSIONS
1. Our studies have shown that the non-replicating HSV-
1 8117/43 construct, in which the Lac Z gene is driven
by combined LAT and MoMuLV LTR promoters, is ca-
pable of expressing the reporter gene in a number of
different neurons within the CNS. The high relative lev-
els of the reporter gene expression were observed in
neuronal cell bodies directly within the inoculated area
but also in afferent projections. The retrograde spread
of the virus from substantia nigra to striatum via stria-
to-nigral projection and from the hippocampus to basal
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Fig. 3C. Substantia nigra 26 days post injection (50 mm sections) (20x).
forebrain through the hippocampo-septal pathway,
demonstrates the feasibility of using the 8117/43 virus
to express genes in areas distal from the injection site,
thus preserving local microanatomy.
2. The propensity of wild-type HSV-1 for retro-
grade and anterograde transport and for trans-neu-
ronal transfer has been used to trace neuronal path-
ways in the brain [11]. However, we found no evi-
dence for the trans-synaptic viral spread. This is
consistent with the earlier finding that after the de-
letion of the immediate early gene ICP4, the ability
of the virus to replicate or reactivate from the latent
state was completely abolished [4,6].
3. Although the length of expression (several weeks)
of HSV-1 8117/43 may not be sufficient to offer an im-
mediate therapeutic promise, this length of expression
and the number of cells expressing the reporter gene
are both significant for more acute basic applications.
These may include in vivo intracerebral gene transfer to
investigate underlying mechanisms and potential cor-
rective therapies for neurodegenerative diseases, espe-
cially those involving the nigrostriatal pathway.
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Figure 4. RT-PCR analysis of dissected regions of rat CNS for
b-galactosidase RNA. 26 days following inoculation of rat CNS
with the HSV-1 vector 8117/43, rats were sacrificed and 12 mm
regions from the substantia nigra dissected and subjected to
RT-PCR analysis as described in Materials and Methods. Primers
specific for b-galactosidase were used and the resulting 293 bp
PCR product is indicated by the arrow. Rats inoculated with either
8117/43, glucose (control), or b-galactosidase-expressing plasmid
DNA mixed with polyethyleneimine (PEI) are compared.
Lane 1  8117/43; Lane 2  Glucose; Lane 3  PEI,
Lane 4  size standards.
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